期刊
PHARMACEUTICS
卷 15, 期 7, 页码 -出版社
MDPI
DOI: 10.3390/pharmaceutics15071848
关键词
cathepsin B; proteolytic activity; enzyme-induced cleavage; peptide linkers; responsive nanocarrier
Cathepsin B is a lysosomal cysteine protease involved in various cellular processes and its overexpression and activity have been linked to pathological conditions such as cancer. Targeting cathepsin B activity has become a promising strategy for tumor-specific therapy and drug delivery. This review summarizes different technologies designed to improve cancer treatments by responsive to cathepsin B activity, which plays a key role in disease progression and treatment response.
Cathepsin B is a lysosomal cysteine protease, contributing to vital cellular homeostatic processes including protein turnover, macroautophagy of damaged organelles, antigen presentation, and in the extracellular space, it takes part in tissue remodeling, prohormone processing, and activation. However, aberrant overexpression of cathepsin B and its enzymatic activity is associated with different pathological conditions, including cancer. Cathepsin B overexpression in tumor tissues makes this enzyme an important target for smart delivery systems, responsive to the activity of this enzyme. The generation of technologies which therapeutic effect is activated as a result of cathepsin B cleavage provides an opportunity for tumor-targeted therapy and controlled drug release. In this review, we summarized different technologies designed to improve current cancer treatments responsive to the activity of this enzyme that were shown to play a key role in disease progression and response to the treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据